RSS

Tecentriq (atezolizumab)

Biotechnology company, Oncolytics Biotech, has announced a clinical collaboration with an academic research group dedicated to clinical and translational research in breast cancer, SOLTI. Read more

News

The US Food and Drug Administration (FDA) has granted breakthrough therapy designation for Roche’s Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) as a first-line treatment for people with advanced or metastatic HCC Read more

News